Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A · kind A · utility
79Cited by
2References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 4, 1995 |
| Grant date | Jan 5, 1999 |
| Priority date | — |
| Expiry date | Dec 4, 2015 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
T cell activation in response to antigen is increased by the administration of binding agents that block CTLA-4 signaling. When CTLA-4 signaling is thus blocked, the T cell response to antigen is released from inhibition. Such an enhanced response is useful for the treatment of tumors, chronic viral infections, and as an adjuvant during immunization.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.